Partner Larry Vernaglia was quoted in an InsideCounsel article on July 24, 2014, titled, “Conflicting Rulings on Obamacare-Related Subsidies Raise New Questions.” The article analyzed two conflicting recent federal appeals court rulings related to the Affordable Care Act. Vernaglia recommends that general counsel follow the developments of these cases in the U.S. Court of Appeals for the District of Columbia Circuit and U.S. Court of Appeals for the 4th Circuit in Richmond, Va.
He was quoted saying “if the D.C. Court of Appeals decision ultimately stands, it could mean, at least, that there will be an increase in the number of uninsured, low-income patients in markets where the states have not implemented an exchange. Of course, this outcome could be some time in the future. Until that time, health care organizations should also be prepared to submit friend of the court (“amicus”) briefs detailing both the legal and practical impact of these decisions.”
He was quoted saying “if the D.C. Court of Appeals decision ultimately stands, it could mean, at least, that there will be an increase in the number of uninsured, low-income patients in markets where the states have not implemented an exchange. Of course, this outcome could be some time in the future. Until that time, health care organizations should also be prepared to submit friend of the court (“amicus”) briefs detailing both the legal and practical impact of these decisions.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”